This article has been cited by
1Adverse drug reactions
Eva Montané,Javier Santesmases
Medicina Clínica (English Edition).2020;154(5)178
[DOI]
2“Fast Track” Development and Approval Process for Heart Failure Therapeutics
L Papadimitriou,J Butler
Clinical Pharmacology & Therapeutics.2017;102(2)184
[DOI]
3The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
Joshua D Wallach,Joseph S Ross,Huseyin Naci
Clinical Trials.2018;15(3)243
[DOI]
4Recent advances in precision oncology research
Ann M. Bode,Zigang Dong
npj Precision Oncology.2018;2(1)243
[DOI]
5The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs
Cristina Scavone,Gabriella di Mauro,Annamaria Mascolo,Liberato Berrino,Francesco Rossi,Annalisa Capuano
Frontiers in Pharmacology.2019;10(1)243
[DOI]
6Pathways to ensure universal and affordable access to hepatitis C treatment
Caitlin H. Douglass,Alisa Pedrana,Jeffrey V. Lazarus,Ellen F. M. ‘t Hoen,Radi Hammad,Ricardo Baptista Leite,Andrew Hill,Margaret Hellard
BMC Medicine.2018;16(1)243
[DOI]
7Reacciones adversas a medicamentos
Eva Montané,Javier Santesmases
Medicina Clínica.2020;154(5)178
[DOI]
8Pulmonary Arterial Hypertension: A Case Study in FDA Expedited Program Designations
Iraj Daizadeh
Therapeutic Innovation & Regulatory Science.2019;53(2)264
[DOI]
  Feedback 
  Subscribe